New early data suggests Precigen Therapeutics’s CAR-T therapy PRGN-3005 could decrease tumour burden in advanced ovarian cancer.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,